CCR2 Antagonists for Monocyte Migration Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases such as asthma and COPD lack effective antagonists for CCR2, which are critical in regulating monocyte trafficking and inflammation, leading to inadequate control of inflammatory processes.
Innovation Solution
Development of novel CCR2 antagonists represented by compounds according to general formula (A-L-D-L'-E-G), including specific groups and structures, which act as pharmacologically acceptable inhibitors to block monocyte CCR2, reducing their migration to inflammation sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory diseases are used, then existing therapeutic options are available, but effective CCR2 antagonists are lacking leading to inadequate control of inflammatory processes
Solution Approach 1:
The patent segments the inflammatory disease treatment by introducing a specific class of CCR2 antagonists (compounds of formula I) that selectively target the CCR2 receptor. This segmentation allows for precise control of monocyte trafficking without affecting other inflammatory pathways, thereby improving reliability of inflammatory control while addressing the lack of versatile CCR2-specific treatments
Solution Approach 2:
The patent applies parameter changes by modifying the chemical structure of CCR2 antagonists through various substituents (R1-R6, X, Y, Z parameters in formula I) to optimize binding affinity and selectivity for CCR2. This enables the development of effective CCR2 antagonists with tailored pharmacological properties, resolving the contradiction between reliability of inflammatory control and availability of versatile antagonists
2Object-generated harmful factors
If monocytes are allowed to migrate to inflammation sites, then natural immune response occurs, but excessive inflammation is promoted by macrophage formation
Solution Approach 1:
The patent introduces CCR2 antagonists as intermediary substances that mediate between monocytes and the inflammation site. By blocking CCR2 receptors on monocytes, these antagonists prevent excessive monocyte recruitment and subsequent macrophage formation, thereby reducing harmful inflammation while preserving necessary immune response regulation
Solution Approach 2:
The patent applies preliminary anti-action by administering CCR2 antagonists before excessive inflammation develops. The antagonists preemptively block CCR2-mediated monocyte trafficking, preventing the cascade that leads to harmful macrophage-induced inflammation, thus controlling inflammation at its source before it becomes excessive
Data Source
AI summary
The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonarydiseases like asthma and COPD.